Evidence map›Paper›PMID 42041388›Full record

ArticleAntibodies (Basel, Switzerland)2026

Development of Bispecific Antibody Targeting Human IL-17A and IL-6.

Beata Pamuła, Martyna Banach, Marta Mikońska, Karolina Korytkowska, Krzysztof Lacek, Oliwia Śniadała, Małgorzata Marczak, Krzysztof Flis, Aleksandra Sowińska, Damian Kołakowski and 4 more

Abstract read
In one paragraph

Article in Antibodies (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Beata PamułaPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Martyna BanachPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Marta MikońskaPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Karolina KorytkowskaPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Krzysztof LacekPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Oliwia ŚniadałaPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Małgorzata MarczakPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Krzysztof FlisPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Aleksandra SowińskaPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Damian KołakowskiPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Jerzy PieczykolanPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Beata ZygmuntPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Maciej WieczorekPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.
Olga AbramczykPreclinical Development Department, Celon Pharma S.A., Ul. Marymoncka 15, 05-152 Kazuń Nowy, Poland.

Funding

National Centre of Research and Development; Celon Pharma POIR.01.02.00-00-0081/18-00
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bispecific antibody (BsAb)cytokinesIL-17AIL-6inflammatory diseasesnanobodiesVHH

Identifiers

PMID42041388
PMCPMC13113400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.